Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of three doses of MOTREM (nangibotide) in patients with septic shock; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Septic Shock

Drugs mentioned

• MOTREM (Nangibotide)

Snippet

Sponsor: Inotrem | Conditions: Shock, Septic | Phase 2 | Status: COMPLETED | Results posted: 2024-10-08